Evidence map›Paper›PMID 28225835›Full record

Trial reportPloS one2017

Mulberry-extract improves glucose tolerance and decreases insulin concentrations in normoglycaemic adults: Results of a randomised double-blind placebo-controlled study.

Mark Lown, Richard Fuller, Helen Lightowler, Ann Fraser, Andrew Gallagher, Beth Stuart, Christopher Byrne, George Lewith

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07494253 (Effects of Mulberry Leaf Extract Formulation on Postprandial Glycemic Levels in Obese Children and Adolescents), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07494253 naenrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Effects of Mulberry Leaf Extract Formulation on Postprandial Glycemic Levels in Obese Children and Adolescents: A Pilot Study (PEDRED)

TypeinterventionalSponsorUniversity of Bari Aldo MoroRan2025 to 2026Enrolled80ConditionsObesityArmsReducose, Placebo
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Guava (Nutrients · 2019
    Trial
  12. Journal of traditional and complementary medicine · 2026
    Article
  13. Review
  14. A Combined Probiotic-International journal of molecular sciences · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Frontiers in clinical diabetes and healthcare · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mark LownPrimary Care & Population Sciences, Faculty of Medicine, University of Southampton, Aldermoor Health Centre, Southampton, United Kingdom.ORCID http://orcid.org/0000-0001-8309-568X
Richard FullerPrimary Care & Population Sciences, Faculty of Medicine, University of Southampton, Aldermoor Health Centre, Southampton, United Kingdom.
Helen LightowlerFunctional Food Centre, Oxford Brooks University, Gipsy Lane Campus, Oxford, United Kingdom.
Ann FraserFunctional Food Centre, Oxford Brooks University, Gipsy Lane Campus, Oxford, United Kingdom.
Andrew GallagherChief Operating Officer, Phynova Group Ltd, 16 Fenlock Court, Long Hanborough, United Kingdom.
Beth StuartPrimary Care & Population Sciences, Faculty of Medicine, University of Southampton, Aldermoor Health Centre, Southampton, United Kingdom.
Christopher ByrneNutrition and Metabolism, Faculty of Medicine, University of Southampton and University Hospitals Southampton, United Kingdom.
George LewithPrimary Care & Population Sciences, Faculty of Medicine, University of Southampton, Aldermoor Health Centre, Southampton, United Kingdom.
University of Southampton · GBOxford Brookes University · GBUniversity Hospital Southampton NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh sugar and refined carbohydrate intake is associated with weight gain, increased incidence of diabetes and is linked with increased cardiovascular mortality. Reducing the health impact of poor quality carbohydrate intake is a public health priority. Reducose, a proprietary mulberry leaf extract (ME), may reduce blood glucose responses following dietary carbohydrate intake by reducing absorption of glucose from the gut.

methodsA double-blind, randomised, repeat measure, phase 2 crossover design was used to study the glycaemic and insulinaemic response to one reference product and three test products at the Functional Food Centre, Oxford Brooks University, UK. Participants; 37 adults aged 19-59 years with a BMI ≥ 20kg/m2 and ≤ 30kg/m2. The objective was to determine the effect of three doses of mulberry-extract (Reducose) versus placebo on blood glucose and insulin responses when co-administered with 50g maltodextrin in normoglycaemic healthy adults. We also report the gastrointestinal tolerability of the mulberry extract.

resultsThirty-seven participants completed the study: The difference in the positive Incremental Area Under the Curve (pIAUC) (glucose (mmol / L x h)) for half, normal and double dose ME compared with placebo was -6.1% (-18.2%, 5.9%; p = 0.316), -14.0% (-26.0%, -2.0%; p = 0.022) and -22.0% (-33.9%, -10.0%; p<0.001) respectively. The difference in the pIAUC (insulin (mIU / L x h)) for half, normal and double dose ME compared with placebo was -9.7% (-25.8%, 6.3%; p = 0.234), -23.8% (-39.9%, -7.8%; p = 0.004) and -24.7% (-40.8%, -8.6%; p = 0.003) respectively. There were no statistically significant differences between any of the 4 groups in the odds of experiencing one or more gastrointestinal symptoms (nausea, abdominal cramping, distension or flatulence).

conclusionsMulberry leaf extract significantly reduces total blood glucose rise after ingestion of maltodextrin over 120 minutes. The pattern of effect demonstrates a classical dose response curve with significant effects over placebo. Importantly, total insulin rises were also significantly suppressed over the same time-period. There were no statistically significant differences between any of the treatment groups (including placebo) in the odds of experiencing one or more gastrointestinal symptoms. Mulberry extract may have multiple modes of action and further studies are necessary to evaluate ME as a potential target for the prevention of type 2 diabetes and the regulation of dysglycaemia.

Indexed as

MorusAdultBlood GlucoseCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleGlucose Tolerance TestHumansInsulinMaleMiddle AgedPlant ExtractsYoung AdultBlood GlucoseInsulinPlant Extracts

Identifiers

PMID28225835
PMCPMC5321430
OpenAlexW2590776674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.